8 Result(s)

Article

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K. Reville, Hagop M. Kantarjian, Farhad Ravandi… in Blood Cancer Journal (2021)

Article

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Mutations of ABL1 are the dominant mechanism of relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). We performed highly accurate Duplex Sequencing of exons 4–10 of ABL1 on bone ma...

Nicholas J. Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna… in Blood Cancer Journal (2020)

Article

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

FLT3-ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3-ITD diversity can further influence clinical outcomes. Addition of FLT3 inhibitors to stand...

Iman Abou Dalle, Ahmad Ghorab, Keyur Patel, Xuemei Wang… in Blood Cancer Journal (2020)

Article

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated i...

Jorge Cortes, Kenji Tamura, Daniel J. DeAngelo, Johann de Bono… in British Journal of Cancer (2018)

Article

Design and rationale for the life after stop** tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduc...

Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang… in BMC Cancer (2018)

Article

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an...

Catriona Jamieson, Robert Hasserjian, Jason Gotlib… in Journal of Translational Medicine (2015)

Article

Erratum: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

Nature Reviews Drug Discovery 10, 127–140 (2011) The information presented in Table 2 on the compound SB1518 was incorrect; the correct information is provided below, and has been corrected online.

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes… in Nature Reviews Drug Discovery (2011)

Article

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

Ehab Atallah, Hagop Kantarjian, Jorge Cortes in Nature Medicine (2007)